IO Biotech Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van IO Biotech is gedaald met een gemiddeld jaarlijks tempo van -26%, terwijl de winst van de sector Biotechs jaarlijks groeide met 19.3%.

Belangrijke informatie

-26.0%

Groei van de winst

72.8%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	n/a
Rendement op eigen vermogen	-124.5%
Nettomarge	n/a
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Opbrengsten en kosten

Hoe IO Biotech geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:IOBT Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	-90	24	72
30 Jun 24	-88	24	70
31 Mar 24	-88	23	70
31 Dec 23	-86	24	68
30 Sep 23	-80	23	60
30 Jun 23	-74	23	53
31 Mar 23	-71	24	49
31 Dec 22	-71	24	47
30 Sep 22	-74	23	49
30 Jun 22	-65	21	43
31 Mar 22	-87	17	38
31 Dec 21	-75	11	30
30 Sep 21	-56	6	16
30 Jun 21	-54	4	15
31 Mar 21	-17	2	10
31 Dec 20	-15	2	8

Kwaliteitswinsten: IOBT is momenteel verliesgevend.

Groeiende winstmarge: IOBT is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: IOBT is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 26% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van IOBT over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: IOBT is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: IOBT heeft een negatief Return on Equity ( -124.5% ), omdat het momenteel verliesgevend is.

IO Biotech Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

IO Biotech, Inc. Announces Data from the NSCLC Cohort in the Phase 2 Basket Trial of IO102-IO103

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-Line Treatment of Advanced Head and Neck Cancer

Price target decreased by 13% to US$8.50

IO Biotech, Inc. Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

New major risk - Financial position

New minor risk - Share price stability

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors

IO Biotech, Inc., Annual General Meeting, Jun 06, 2024

New minor risk - Market cap size

IO Biotech Announces Marjan Shamsaei as Senior Vice President

IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103

IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer

IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting

New major risk - Revenue and earnings growth

New minor risk - Market cap size

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

High number of new directors

IO Biotech Appoints Helen Collins, Md, to Its Board of Directors

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

New minor risk - Share price stability

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Price target decreased by 15% to US$9.67

IO Biotech, Inc. Appoints Heidi Hunter to Its Board of Directors

IO Biotech, Inc. announced that it expects to receive $75.057935 million in funding from a group of investors

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer Center

IO Biotech, Inc. Announces Executive Changes

New minor risk - Share price stability

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech, Inc. Appoints Christine Richter as Senior Vice President, Commercial and Program Lead

Chief Financial Officer recently bought US$58k worth of stock

IO Biotech Appoints Devin Smith as General Counsel and Chief Compliance Officer

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Price target decreased to US$17.50

IO Biotech, Inc. Announces Appointment of Amy Sullivan as Chief Financial Officer

IO Biotech names new CFO

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech GAAP EPS of -$0.64

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma

IO Biotech, Inc. Announces Executive Changes

High number of new directors

High number of new directors

IO Biotech, Inc. Announces its Two Directors Not Stand for Re-Election

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

IO Biotech, Inc. Announces Appointment of David V. Smith to Board of Directors

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden